Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenesis, Mass General Researcher Launch Proteomics-Based Partnership

NEW YORK, July 23-Massachusetts General Hospital and NeoGenesis Pharmaceuticals announced today a four-year proteomics-based drug discovery collaboration.

Through the partnership, MGH molecular biologist Brian Seed will provide the company with proteins believed to play a role in disease.  NeoGenesis will use its compound libraries and ligand screening system to identify compounds that interact with these proteins. MGH will characterize the compounds in assays and animal models, and NeoGenesis will take over clinical development.


The partners will look for drugs to target cancer and inflammatory disease. Financial details were not disclosed.


Seed studies gene expression in angiogenesis and signal transduction in the immune response, and has a proteomics facility in Cambridge, Mass that can produce and characterize disease-associated proteins.


The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.